Bevacizumab-induced nasal septum perforation [1]

Oncologist

Volumn 11, Issue 1, 2006, Pages 85-86

  Fakih, Marwan G ^a   Lombardo, Jeffrey C ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BEVACIZUMAB; CLOPIDOGREL; FLUOROURACIL; FOLINIC ACID; IRBESARTAN; METOPROLOL; METOPROLOL TARTRATE; OXALIPLATIN;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLON CANCER; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; EPISTAXIS; HUMAN; HYPERTENSION; LETTER; LIVER METASTASIS; MALE; NOSE SEPTUM PERFORATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NASAL SEPTUM; NOSE DISEASES;

EID: 31444448742     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.11-1-85     Document Type: Letter

References (5)

1. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
3. Giantonio B, Catalano P, Meropol N et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2005;23:1s. Abstract 2.
4. Hurwitz H, Fehrenbacher L, Cartwright T et al. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J Clin Oncol 2004;22(14s):3702.
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027.